{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:14:30Z","timestamp":1789006470010,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd007744","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,10,23]],"date-time":"2014-10-23T00:00:00Z","timestamp":1414022400000}}],"reference-count":52,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007744.pub2","type":"journal-article","created":{"date-parts":[[2014,10,23]],"date-time":"2014-10-23T16:13:51Z","timestamp":1414080831000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease"],"prefix":"10.1002","volume":"2014","author":[{"given":"Xin-Pu","family":"Miao","sequence":"first","affiliation":[{"name":"Hai Nan Provincial People's Hospital; Department of Gastroenterology; 19 Xiu Hua Road, Xiu Ying District Hai Kou City Han Nan Province China 570311"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Sheng","family":"Li","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Zhengzhou University; Department of Gastroenterology; Zhengzhou Henan Province China 450052"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ouyang","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Department of Gastroenterology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Wei","family":"Hu","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Department of Gastroenterology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Guang An Men Hospital, China Academy of Chinese Medical Sciences; Department of Acupuncture and Moxibustion; No. 5, Bei Xian Ge Street Beijing China 100053"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Yan","family":"Li","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University; Department of Chemotherapy; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,10,23]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD007744.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1572-0241.2006.00384.x","article-title":"The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases","volume":"101","author":"Miedany","year":"2006","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD007744.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cgh.2005.12.002","article-title":"Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study","volume":"4","author":"Sandborn","year":"2006","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD007744.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2036.2004.01907.x","article-title":"Rofecoxib and early relapse of inflammatory bowel disease: An open-label trial","volume":"19","author":"Biancone","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD007744.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/j.1572-0241.2001.03730.x","article-title":"Exacerbation of inflammatory bowel disease associated with use of celecoxib","volume":"96","author":"Bonner","year":"2001","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD007744.pub2-BIB0005|cit5","first-page":"511","article-title":"Acute ulcerative colitis in a patient treated with rofecoxib who took aspirin as self-medication","volume":"27","author":"Charachon","year":"2003","journal-title":"Gastroent\u00e9rologie Clinique et Biologique."},{"issue":"1-2","key":"10.1002\/14651858.CD007744.pub2-BIB0006|cit6","first-page":"105","article-title":"Rofecoxib-associated upper gastrointestinal bleed: a case report","volume":"69","author":"Freedman","year":"2002","journal-title":"Mount Sinai Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007744.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1572-0241.2002.05631.x","article-title":"Rofecoxib and cytomegalovirus in acute flare-up of ulcerative colitis: coprecipitants or coincidence?","volume":"97","author":"Goh","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD007744.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1111\/j.1572-0241.2002.07142.x","article-title":"Exacerbation of Crohn's colitis with severe colonic hemorrhage in a patient on rofecoxib","volume":"97","author":"Gornet","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD007744.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1572-0241.2002.05608.x","article-title":"Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease","volume":"97","author":"Mahadevan","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD007744.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00054725-200407000-00005","article-title":"The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease","volume":"10","author":"Matuk","year":"2004","journal-title":"Inflammatory Bowel Diseases"},{"issue":"11","key":"10.1002\/14651858.CD007744.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1046\/j.1365-2036.2003.01596.x","article-title":"An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia","volume":"17","author":"Reinisch","year":"2003","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD007744.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0755-4982(05)83940-5","article-title":"Ulcerating haemorrhagic colitis induced by celecoxib","volume":"34","author":"Rey","year":"2005","journal-title":"Presse M\u00e9dicale"},{"issue":"2","key":"10.1002\/14651858.CD007744.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1542-3565(05)00980-8","article-title":"Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease","volume":"4","author":"Takeuchi","year":"2006","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD007744.pub2-BIB0014|cit14","first-page":"142","article-title":"Rofecoxib and inflammatory bowel disease: clinical and pathologic observations","volume":"39","author":"Wilcox","year":"2005","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD007744.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0889-8553(05)70056-X","article-title":"Epidemiology and the natural course of inflammatory bowel disease","volume":"28","author":"Andres","year":"1999","journal-title":"Gastroenterology Clinics of North America"},{"issue":"8","key":"10.1002\/14651858.CD007744.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1517\/14656566.2013.783568","article-title":"Valdecoxib : the rise and fall of a COX-2 inhibitor","volume":"14","author":"Atukorala","year":"2013","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD007744.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"C62","DOI":"10.1016\/S0399-8320(04)95280-3","article-title":"Gastrointestinal complications related to NSAIDs","volume":"28 Spec No 3","author":"Beaugerie","year":"2004","journal-title":"Gastroent\u00e9rologie Clinique et Biologique"},{"issue":"6","key":"10.1002\/14651858.CD007744.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/0016-5085(93)90667-2","article-title":"Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans","volume":"104","author":"Bjarnason","year":"1993","journal-title":"Gastroenterology"},{"issue":"21","key":"10.1002\/14651858.CD007744.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"10.1002\/14651858.CD007744.pub2-BIB0020|cit20","first-page":"2648-50; author","article-title":"Cardiovascular risk associated with celecoxib","volume":"352","author":"Brophy","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007744.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.burns.2004.10.017","article-title":"Valdecoxib-associated acute generalized exanthematous pustulosis","volume":"31","author":"Byerly","year":"2005","journal-title":"Burns"},{"issue":"1","key":"10.1002\/14651858.CD007744.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/1529-0131(200001)43:1<4::AID-ANR2>3.0.CO;2-V","article-title":"Basic biology and clinical application of specific cyclooxygenase-2 inhibitors","volume":"43","author":"Crofford","year":"2000","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD007744.pub2-BIB0023|cit23","article-title":"Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen","author":"Vecchis","journal-title":"Minerva Cardioangiologica"},{"issue":"7109","key":"10.1002\/14651858.CD007744.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD007744.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"229-30, 233-4","DOI":"10.1080\/00325481.1989.11704368","article-title":"Arthritis and the gut","volume":"86","author":"Finch","year":"1989","journal-title":"Postgraduate Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007744.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/imj.12158","article-title":"Lumiracoxib-induced cholestatic liver injury","volume":"43","author":"Fok","year":"2013","journal-title":"Internal Medicine Journal"},{"issue":"3","key":"10.1002\/14651858.CD007744.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/01.CIR.0000155081.76164.17","article-title":"Parecoxib, valdecoxib, and cardiovascular risk","volume":"111","author":"Furberg","year":"2005","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD007744.pub2-BIB0028|cit28","first-page":"703","article-title":"Arthritic manifestations of inflammatory bowel disease","volume":"83","author":"Gravallese","year":"1988","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD007744.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005792-197609000-00004","article-title":"The extra-intestinal complications of Crohn's disease and ulcerative colitis: A study of 700 patients","volume":"55","author":"Greenstein","year":"1976","journal-title":"Medicine (Baltimore)"},{"issue":"1A","key":"10.1002\/14651858.CD007744.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"33S","DOI":"10.1016\/S0002-9343(00)00634-3","article-title":"Prospects for changing the burden of nonsteroidal anti-inflammatory drug toxicity","volume":"110","author":"Griffin","year":"2001","journal-title":"American Journal of Medicine"},{"issue":"7650","key":"10.1002\/14651858.CD007744.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007744.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1097\/00005344-200605001-00013","article-title":"NSAIDs, coxibs, and the intestine","volume":"47 Suppl 1","author":"Hawkey","year":"2006","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"7414","key":"10.1002\/14651858.CD007744.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007744.pub2-BIB0034|cit34","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"9450","key":"10.1002\/14651858.CD007744.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(04)17523-5","article-title":"Vioxx, the implosion of Merck, and aftershocks at the FDA","volume":"364","author":"Horton","year":"2004","journal-title":"Lancet"},{"issue":"9450","key":"10.1002\/14651858.CD007744.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(04)17514-4","article-title":"Risk of cardiovascular events and rofecoxib: cumulative meta-analysis","volume":"364","author":"J\u00fcni","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD007744.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"issue":"7119","key":"10.1002\/14651858.CD007744.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/bmj.315.7119.1333","article-title":"Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study","volume":"315","author":"MacDonald","year":"1997","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD007744.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.clinthera.2005.07.019","article-title":"Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis","volume":"27","author":"Matchaba","year":"2005","journal-title":"Clinical Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD007744.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa050330","article-title":"Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery","volume":"352","author":"Nussmeier","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007744.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0022-5223(03)00125-9","article-title":"Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery","volume":"125","author":"Ott","year":"2003","journal-title":"Journal of Thoracic and Cardiovascular Surgery"},{"issue":"6","key":"10.1002\/14651858.CD007744.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/j.1440-1746.2011.07036.x","article-title":"Severe acute liver injury associated with lumiracoxib","volume":"27","author":"Pillans","year":"2012","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD007744.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0025-7125(16)30585-5","article-title":"Extraintestinal and systemic manifestations of inflammatory bowel disease","volume":"74","author":"Rankin","year":"1990","journal-title":"Medical Clinics of North America"},{"key":"10.1002\/14651858.CD007744.pub2-BIB0044|cit44","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"9435","key":"10.1002\/14651858.CD007744.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial","volume":"364","author":"Schnitzer","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD007744.pub2-BIB0046|cit46","first-page":"216","article-title":"Selected rheumatologic and dermatologic manifestations of inflammatory bowel disease","volume":"83","author":"Schorr-Lesnick","year":"1988","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD007744.pub2-BIB0047|cit47","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Sch\u00fcnemann","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD007744.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial","volume":"123","author":"Silverstein","year":"1995","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007744.pub2-BIB0049|cit49","first-page":"285","article-title":"Epidemiology of inflammatory bowel disease in Asia","volume":"26","author":"Sood","year":"2007","journal-title":"Indian Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD007744.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jbspin.2004.10.004","article-title":"Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum","volume":"72","author":"Thi\u00e9fin","year":"2005","journal-title":"Joint, Bone, Spine"},{"issue":"25","key":"10.1002\/14651858.CD007744.pub2-BIB0051|cit51","first-page":"232","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nature: New Biology"},{"issue":"6","key":"10.1002\/14651858.CD007744.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/archderm.143.6.711","article-title":"Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"143","author":"Ziemer","year":"2007","journal-title":"Archives of Dermatology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007744.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T03:42:56Z","timestamp":1719373376000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007744.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,23]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007744.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,23]]}}}